Literature DB >> 20477910

Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation.

Scoty M Hearst1, Mariper E Lopez, Qingmei Shao, Yong Liu, Parminder J S Vig.   

Abstract

Spinocerebellar ataxia 1 (SCA1) is a dominantly inherited neurodegenerative disease associated with progressive ataxia resulting from the loss of cerebellar Purkinje cells (PCs) and neurons in the brainstem. In PCs of SCA1 transgenic mice, the disease causing ataxin-1 protein mediates the formation of S100B containing cytoplasmic vacuoles and further self-aggregates to form intranuclear inclusions. The exact function of the ataxin-1 protein is not fully understood. However, the aggregation and neurotoxicity of the mutant ataxin-1 protein is dependent on the phosphorylation at serine 776 (S776). Although protein kinase A (PKA) has been implicated as the S776 kinase, the mechanism of PKA/ataxin-1 regulation in SCA1 is still not clear. We propose that a dopamine D(2) receptor (D2R)/S100B pathway may be involved in modulating PKA activity in PCs. Using a D2R/S100B HEK stable cell line transiently transfected with GFP-ataxin-1[82Q], we demonstrate that stimulation of the D2R/S100B pathway caused a reduction in mutant ataxin-1 S776 phosphorylation and ataxin-1 aggregation. Activation of PKA by forskolin resulted in an enhanced S776 phosphorylation and increased ataxin-1 nuclear aggregation, which was suppressed by treatment with D2R agonist bromocriptine and PKA inhibitor H89. Furthermore, treating SCA1 transgenic PC slice cultures with forskolin induced neurodegenerative morphological abnormalities in PC dendrites consistent with those observed in vivo. Taken together our data support a mechanism where PKA dependent mutant ataxin-1 phosphorylation and aggregation can be regulated by D2R/S100B signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20477910      PMCID: PMC2921766          DOI: 10.1111/j.1471-4159.2010.06791.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  63 in total

1.  The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia.

Authors:  D H Geschwind; S Perlman; C P Figueroa; L J Treiman; S M Pulst
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

Review 2.  Bromocriptine versus levodopa in early Parkinson's disease.

Authors:  C Ramaker; J J van Hilten
Journal:  Cochrane Database Syst Rev       Date:  2000

3.  Effects of PKA and PKC modulators on high affinity glutamate uptake in primary neuronal cell cultures from rat cerebral cortex.

Authors:  S Lortet; D Samuel; L Had-Aissouni; F Masmejean; L Kerkerian-Le Goff; P Pisano
Journal:  Neuropharmacology       Date:  1999-03       Impact factor: 5.250

4.  Role of protein kinase A in LPS-induced activation of NF-kappa B proteins of a mouse macrophage-like cell line, J774.

Authors:  M Muroi; T Suzuki
Journal:  Cell Signal       Date:  1993-05       Impact factor: 4.315

5.  Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1.

Authors:  C J Cummings; M A Mancini; B Antalffy; D B DeFranco; H T Orr; H Y Zoghbi
Journal:  Nat Genet       Date:  1998-06       Impact factor: 38.330

6.  SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat.

Authors:  E N Burright; H B Clark; A Servadio; T Matilla; R M Feddersen; W S Yunis; L A Duvick; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1995-09-22       Impact factor: 41.582

7.  Phosphorylation of ATXN1 at Ser776 in the cerebellum.

Authors:  Nathan D Jorgensen; J Michael Andresen; Sara Lagalwar; Ben Armstrong; Sam Stevens; Courtney E Byam; Lisa A Duvick; Shaojuan Lai; Paymaan Jafar-Nejad; Huda Y Zoghbi; H Brent Clark; Harry T Orr
Journal:  J Neurochem       Date:  2009-05-15       Impact factor: 5.372

Review 8.  Forskolin: a unique diterpene activator of cyclic AMP-generating systems.

Authors:  K B Seamon; J W Daly
Journal:  J Cyclic Nucleotide Res       Date:  1981

9.  Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model.

Authors:  Kei Watase; Jennifer R Gatchel; Yaling Sun; Effat Emamian; Richard Atkinson; Ronald Richman; Hidehiro Mizusawa; Harry T Orr; Chad Shaw; Huda Y Zoghbi
Journal:  PLoS Med       Date:  2007-05       Impact factor: 11.069

10.  Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1.

Authors:  Robert Goold; Michael Hubank; Abigail Hunt; Janice Holton; Rajesh P Menon; Tamas Revesz; Massimo Pandolfo; Antoni Matilla-Dueñas
Journal:  Hum Mol Genet       Date:  2007-06-28       Impact factor: 6.150

View more
  13 in total

1.  The design and delivery of a thermally responsive peptide to inhibit S100B-mediated neurodegeneration.

Authors:  S M Hearst; L R Walker; Q Shao; M Lopez; D Raucher; P J S Vig
Journal:  Neuroscience       Date:  2011-09-17       Impact factor: 3.590

Review 2.  Beyond the glutamine expansion: influence of posttranslational modifications of ataxin-1 in the pathogenesis of spinocerebellar ataxia type 1.

Authors:  Hyoungseok Ju; Hiroshi Kokubu; Janghoo Lim
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

3.  Knockdown of acid-sensing ion channel 1a (ASIC1a) suppresses disease phenotype in SCA1 mouse model.

Authors:  Parminder J S Vig; Scoty M Hearst; Qingmei Shao; Maripar E Lopez
Journal:  Cerebellum       Date:  2014-08       Impact factor: 3.847

4.  Glial S100B protein modulates mutant ataxin-1 aggregation and toxicity: TRTK12 peptide, a potential candidate for SCA1 therapy.

Authors:  Parminder J S Vig; Scoty Hearst; Qingmei Shao; Mariper E Lopez; Henry A Murphy; Eshan Safaya
Journal:  Cerebellum       Date:  2011-06       Impact factor: 3.847

5.  Genome-wide association study of a quantitative disordered gambling trait.

Authors:  Penelope A Lind; Gu Zhu; Grant W Montgomery; Pamela A F Madden; Andrew C Heath; Nicholas G Martin; Wendy S Slutske
Journal:  Addict Biol       Date:  2012-07-11       Impact factor: 4.280

6.  Reduction of protein kinase A-mediated phosphorylation of ATXN1-S776 in Purkinje cells delays onset of Ataxia in a SCA1 mouse model.

Authors:  Judit M Pérez Ortiz; Nissa Mollema; Nicholas Toker; Carolyn J Adamski; Brennon O'Callaghan; Lisa Duvick; Jillian Friedrich; Michael A Walters; Jessica Strasser; Jon E Hawkinson; Huda Y Zoghbi; Christine Henzler; Harry T Orr; Sarita Lagalwar
Journal:  Neurobiol Dis       Date:  2018-05-11       Impact factor: 5.996

7.  Focused cerebellar laser light induced hyperthermia improves symptoms and pathology of polyglutamine disease SCA1 in a mouse model.

Authors:  Scoty M Hearst; Qingmei Shao; Mariper Lopez; Drazen Raucher; Parminder J S Vig
Journal:  Cerebellum       Date:  2014-10       Impact factor: 3.847

Review 8.  The unstable repeats--three evolving faces of neurological disease.

Authors:  David L Nelson; Harry T Orr; Stephen T Warren
Journal:  Neuron       Date:  2013-03-06       Impact factor: 17.173

9.  Expression of Drosophila Matrix Metalloproteinases in Cultured Cell Lines Alters Neural and Glial Cell Morphology.

Authors:  Scoty Hearst; Andrea Bednářová; Benjamin Draughn; Kennadi Johnson; Desiree Mills; Cendonia Thomas; Jendaya Scales; Eadie T Keenan; Jewellian V Welcher; Natraj Krishnan
Journal:  Front Cell Dev Biol       Date:  2021-05-13

10.  Levels of S100B are raised in female patients with schizophrenia.

Authors:  Kara O'Connell; Jogin Thakore; Kumlesh K Dev
Journal:  BMC Psychiatry       Date:  2013-05-24       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.